NCT03463525 - Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 24, 2018

Primary Completion Date

March 19, 2020

Study Completion Date

October 5, 2020

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Osimertinib

Osimertinib 80 mg once daily p.o. will be taken continuously by the patient from the day of the second PET exam.

DRUG

[11C]osimertinib

Patients will receive 3 single IV microdose administrations of \[11C\]osimertinib and PET exams on: Day 1, Day 2 (or up to Day 8) and Day 29.

Trial Locations (1)

Research Site, Stockholm